Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Economic impact of diagnostic testing
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of EGFR-mutated non-small-cell lung cancer

Economic impact of diagnostic testing

2 evidence topics · 1 source

Biomarker-testing cost components

“Testing costs (including retesting) encompassed personnel costs, consumables, equipment, and overheads.” (opens the source at this quote in a new tab)

NGS versus single-gene testing: current-practice scenario, 2023–2024

“26% lower for NGS than for SGT in the CP scenario.” (opens the source at this quote in a new tab)